ChiCTR2200060886Not yet recruiting
Untitled Trial
A phase Ⅰ/Ⅱ study of Almonertinib with Bevacizumab in the first-line treatment of EGFR-mutant non-squamous non-small cell lung cancer patients with brain metastases
The Second Affiliated Hospital of Chongqing Medical UniversityPhase 1/2Chinese Clinical Trial Registry
Study focus
- Disease/Condition
- lung cancer
Sponsor & location
- Primary sponsor
- The Second Affiliated Hospital of Chongqing Medical University
- Funder
- self-financing
- Location
- China
Timeline & enrollment
- Phase
- Phase 1/2
- Start date
- N/A
- End date
- Jun 30, 2024
ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2200060886
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2200060886 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by The Second Affiliated Hospital of Chongqing Medical University and is currently Not yet recruiting. The study focuses on lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.